Painless People and Unbreakable Bones Became a $2.1 Billion Drug and a Pain Pill Aimed at the Channel Next Door
The sales pitch, around 2016, was that a few human bodies were walking instruction manuals. Find the person who cannot feel a knife. Find the person whose skeleton laughs off a car wreck. Read the broken gene. Sell the drug that copies what the gene already does. A decade later the manuals have brand names, and the two readouts could not be more different. One is a $2.1 billion osteoporosis franchise. The other is a new pain pill that is finally showing up in hospital order sets, and that a loud group of patients says does not do what the press releases imply.
Steven Pete, in Washington state, was born with a loss-of-function change in SCN9A. That gene builds NaV1.7, a sodium channel that peripheral nerves use to pass pain signals. Without a working channel, the signal does not start. Pete has described injuries that would drop another person, and a left leg damaged so thoroughly, because he could not feel the damage accumulating, that amputation was on the table. The same gene, hit in the opposite direction, causes syndromes of unbearable pain. The drug industry spent years trying to block NaV1.7 in ordinary patients just enough to mimic Pete’s mercy without mimicking his danger. Most of those molecules failed. They were not selective enough, they numbed the wrong fibers, or they simply did not beat a sugar pill in people whose pain was more complicated than a textbook channel.
The pill that actually reached pharmacies does not hit NaV1.7. On January 30, 2025, the U.S. Food and Drug Administration approved Journavx, suzetrigine, from Vertex Pharmaceuticals, for moderate to severe acute pain in adults. It is an oral blocker of NaV1.8, a related channel on the same pain-sensing neurons, and the first drug in a new non-opioid class in more than twenty years. The approval rested on surgical trials, including abdominoplasty and bunionectomy, that measured pain scores over 48 hours against placebo, with an opioid combination as a reference. Vertex’s scientific bet was that the lesson from painless people was the neighborhood, the peripheral sodium channel, not the single address SCN9A. The company has said it is still working on NaV1.7 molecules that could be used alone or stacked with a NaV1.8 blocker. The gene that made the magazine stories is not the gene in the bottle.
The commercial numbers, as Vertex reported them and as Pharmacy Times tallied in August 2026, are no longer a launch anecdote. Journavx brought in $50 million in the second quarter of 2026, up 71 percent from the first quarter and more than four times the $12 million of the second quarter of 2025. About 535,000 prescriptions were filled that quarter. The first half of 2026 came to roughly 900,000 fills across hospitals and retail pharmacies, which is not the same thing as 900,000 patients. Reimbursed access, the company said, reached about 260 million people in the United States through commercial plans and government programs, including additional Medicare Part D pharmacy-benefit deals and 23 state Medicaid programs. Vertex raised its full-year 2026 revenue forecast to $13.1 billion to $13.2 billion and said it expects its products outside cystic fibrosis, Journavx among them, to clear at least $500 million in 2026. List prices discussed in trade coverage sit near $15 a tablet. A copay and a list price are not the same number, and a hospital that adds the drug to a protocol is not a patient who can find it at a corner pharmacy on a Friday night.
A phase 4 study published in Pain and Therapy in 2026, and covered by Managed Healthcare Executive, is the other half of the sales story, and it is smaller than the revenue. Forty-seven people having laparoscopic or arthroscopic surgery took a 100-milligram dose before the operation, then 50 milligrams every 12 hours for up to 14 days, together with acetaminophen and ibuprofen. Opioids were allowed as rescue. The investigators reported that 76.1 percent never needed that rescue, and that 90.9 percent rated their pain control good, very good, or excellent. The people who did use a rescue opioid averaged a short course, on the order of two days. A parallel look at plastic-surgery patients, presented around the PainConnect 2026 meeting, pointed the same direction. Forty-seven patients is a case series with a protocol, not a new pivotal trial. It cannot settle whether suzetrigine replaces opioids. It can show that, inside a multimodal plan, a lot of straightforward operations did not need them.
Critics have not let the 48-hour window go. Patient advocates argue that “non-opioid” is being lobbied into hospital policy and into veterans’ legislation ahead of evidence that the drug beats hydrocodone where it matters, and that chronic pain was never the approved use. Voices for Non-Opioid Choices, a coalition pressing for wider access after surgery, is on the other side of that argument, and opponents have tied the campaign’s lobbying to Vertex.
The bone manual paid off on a cleaner clock, and with a warning label that should kill the word superhuman. Sclerosteosis, a rare condition studied in South African families and in patients including Timothy Dreyer of Johannesburg, comes from mutations in SOST. The gene’s protein, sclerostin, is a brake on bone formation. Lose the brake and bone keeps being laid down. People with the condition have bones that are extraordinarily dense and skulls that can trap nerves. Amgen and UCB turned that brake into a drug target. Romosozumab, sold as Evenity, is an antibody that blocks sclerostin for a year of monthly injections. Unlike bisphosphonates, which mainly slow bone loss, it also tells the body to build. The FDA refused the first bid, then approved Evenity on April 9, 2019, for postmenopausal women at high risk of fracture. Hylton Joffe, the FDA official who oversaw the review, said patients had to be chosen carefully. The label carries a boxed warning for heart attack and stroke. The injection course stops at twelve months because the bone-building effect fades, and patients are typically moved to an anti-resorptive drug afterward.
Amgen’s 2025 letter to shareholders, published in 2026, said Evenity sales grew 34 percent to $2.1 billion. In the annual filing, U.S. sales were $1.6 billion of that, up 41 percent, with the rest of the world at $500 million. Volume, not a secret price hike, drove the increase. The company estimates about two million people in the United States fit the high-risk profile the drug was built for. A mutation found in a small number of families is now a blockbuster. That is the business plan the 2016 reporting was describing, stripped of the comic-book noun.
The ethical problem did not get solved by the revenue. Pete did not patent NaV1.7. The families who lived with sclerosteosis did not set Evenity’s price. A company can sequence a consenting patient, patent a composition aimed at the pathway, and owe that patient nothing that looks like a royalty. Artificial intelligence has shortened the comparison of genomes from months to hours, which means the next “instruction manual” will be found faster and argued over in the same vacuum. Who consented, who can withdraw, who gets the drug when the list price is built for a specialty pharmacy, and who is left on an opioid because a new sodium-channel pill is approved for acute pain and not for the years that follow: those are the questions The AEGIS Alliance keeps putting next to the sales charts.
The hunt has widened past pain and bone, toward people who stay thin on a common diet, people who shrug off infections, and lineages with unusually late disease. Those programs will produce their own press releases. The two that already landed are enough to retire the slogan. Superhuman DNA was a sourcing strategy. The products are a heart-risk bone drug that made $2.1 billion and a pain drug that blocks the channel next door to the one a painless man was born without.
The AEGIS Alliance has tracked the other side of this medicine cabinet for years, including the U.S. government’s own patent on cannabinoids and the early clinical claim that cannabis could blunt opioid dependence. More of the desk is filed under Health and Science.
